HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Frutarom to acquire Abaco

This article was originally published in The Rose Sheet

Executive Summary

Frutarom U.S.A. Inc. - a wholly owned subsidiary of Frutarom Industries - has signed an agreement to acquire the flavor and fragrance ingredient supplier Abaco for $4 mil. with assumption of the company's $1.1 mil. debt, firm announces July 4. "The acquisition is expected to enhance Frutarom's activities in the U.S., which is a strategic market for the Frutarom Group, and to expand the product line offered by the Fine Ingredients Division to its customers in the U.S. and globally," firm says. "The acquisition of Abaco, the fifth acquisition Frutarom has made this year, demonstrates the continued implementation of the rapid growth strategy of the Frutarom Group, which is already one of the ten largest companies in the world in the flavor and fragrance field said," President and CEO Ori Yehudai remarks...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel